13,02 $
4,49 %gestern
Nasdaq, 1. März, 22:00 Uhr
ISIN
US92337C1045
Symbol
VSTM
Berichte
Sektor
Industrie

Verastem, Inc. Aktie News

Positiv
InvestorPlace
24 Tage alt
In the vast landscape of today's markets, artificial intelligence (AI) is reshaping investment strategies. Therefore, AI stock picks are as relevant as ever.
Positiv
Seeking Alpha
24 Tage alt
Rolling NDA submission of avutometinib + defactinib for the treatment of patients with low-grade serous ovarian cancer is expected in the 1st half of 2024, with possible commercialization in 2025. Results from two studies, RAMP-203 and RAMP-204, each using avutometinib with two different types of KRAS G12C inhibitors for the treatment of KRAS G12C NSCLC, expected mid-2024. The global non-small ...
Neutral
Business Wire
etwa ein Monat alt
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic priorities and upcoming catalysts to support advancement of its clinical programs in RAS pathway-driven cancers. “We have made significant progress in our commitment to advancing new solutions for RAS pathway-drive...
Neutral
Business Wire
etwa ein Monat alt
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Verastem Oncology's investigational RAF/MEK clamp, avutometinib, in combination with Amgen's KRAS G12C inhibitor, LUMAKRASTM (sotorasib), for the trea...
Neutral
MCAP MediaWire
etwa 2 Monate alt
New York, N.Y., January 12, 2024 – In concert with Cervical Health Awareness Month, PRISM MarketView has added Verastem, Inc., a biopharmaceutical company focused on the development and commercialization of new medicines for patients combating various types of cancer to its Emerging Women's Health Index.
Neutral
Business Wire
etwa 2 Monate alt
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on Thursday, January 18, 2024 at 4:00 p.m. ET. To access the live webcast of the fireside chat, please co...
Neutral
Business Wire
etwa 2 Monate alt
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 19,251 shares of its common stock to six new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees' acceptance of emplo...
Neutral
Business Wire
2 Monate alt
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential best-in-class KRAS G12D oral inhibitor as the lead program of its discovery and development collaboration with GenFleet Therapeutics (“GenFleet”). “We are pleased to announce this oral KRAS G12D inhibito...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen